Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term phase III safety and efficacy study of TAC-202 (bilastine) in chronic idiopathic urticaria and pruritus with skin diseases
jRCT2080222478Phase 3
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bilastine in chronic idiopathic urticaria (CIU) and pruritus, sponsored by Taiho Pharmaceutical Co., Ltd.
02
Drugs
bilastine
03
Conditions
chronic idiopathic urticaria (CIU)pruritus
Beyond the preview
Go deeper on jRCT2080222478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222478.